Alzheimer's Disease Program
Alzheimer's Disease
About Roche
F. Hoffmann-La Roche Ltd is a Swiss multinational healthcare company headquartered in Basel, with over 125 years of history in pharmaceutical and diagnostic innovation. The company operates through two main divisions - Roche Pharmaceuticals and Roche Diagnostics - focusing on preventing, stopping, and curing diseases with high societal burden. Roche is publicly traded and maintains a strong commitment to research and development, with a strategy centered on personalized healthcare and integrated diagnostic-therapeutic solutions.
View full company profileAbout Biogen
Biogen stands as a premier biotechnology company focused on developing innovative therapies for complex neurological, immunological, and rare diseases with significant unmet medical needs. With decades of pioneering work in multiple sclerosis and recent expansions into nephrology through the acquisition of Human Immunology Biosciences, the company maintains a diverse pipeline spanning Alzheimer's disease, ALS, lupus, and other challenging conditions. Biogen's commitment to scientific excellence is demonstrated through substantial annual R&D investment of $2 billion and a global team of over 1,300 research professionals driving innovation from discovery to commercialization.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |
| NVG-291 | NervGen Pharma | Phase 1b/2a |